ORBITA-2
2023
A Placebo-Controlled Trial of PCI for Stable Angina
In 301 patients with stable angina on no antianginal medication, PCI improved the angina symptom score compared with a placebo procedure.
Result
Efficacy: Angina symptom scoreOR 2.21 · P < 0.001
Below 1 favours a placebo procedure, above 1 favours PCI.
Also reported: Corrects the negative ORBITA result.
- Subtopic
- Revascularisation
- Design
- Sham-controlled, double-blind RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 CCS
- Source
- Rajkumar CA, et al. N Engl J Med. 2023;389(25):2319-2330.doi 10.1056/NEJMoa2310610
Discussion & critique
Removing background antianginals (unlike ORBITA) unmasked a genuine symptom benefit of PCI. The endpoint is symptom-based rather than exercise time; the procedural placebo effect remains relevant.